Literature DB >> 22992037

Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.

Anshuman Dixit1, Gennady M Verkhivker.   

Abstract

The rapidly growing wealth of structural and functional information about kinase genes and kinase inhibitors that is fueled by a significant therapeutic role of this protein family provides a significant impetus for development of targeted computational screening approaches. In this work, we explore an ensemble-based, protein-centric approach that allows for simultaneous virtual ligand screening against multiple kinase genes and multiple kinase receptor conformations. We systematically analyze and compare the results of ligand-based and protein-centric screening approaches using both single-receptor and ensemble-based docking protocols. A panel of protein kinase targets that includes ABL, EGFR, P38, CDK2, TK, and VEGFR2 kinases is used in this comparative analysis. By applying various performance metrics we have shown that ligand-centric shape matching can provide an effective enrichment of active compounds outperforming single-receptor docking screening. However, ligand-based approaches can be highly sensitive to the choice of inhibitor queries. Employment of multiple inhibitor queries combined with parallel selection ranking criteria can improve the performance and efficiency of ligand-based virtual screening. We also demonstrated that replica-exchange Monte Carlo docking with kinome-based ensembles of multiple crystal structures can provide a superior early enrichment on the kinase targets. The central finding of this study is that incorporation of the template-based structural information about kinase inhibitors and protein kinase structures in diverse functional states can significantly enhance the overall performance and robustness of both ligand and protein-centric screening strategies. The results of this study may be useful in virtual screening of kinase inhibitors potentially offering a beneficial spectrum of therapeutic activities across multiple disease states.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22992037     DOI: 10.1021/ci3002638

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  8 in total

1.  Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.

Authors:  David K Johnson; John Karanicolas
Journal:  J Chem Inf Model       Date:  2016-01-14       Impact factor: 4.956

2.  DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.

Authors:  Ragul Gowthaman; Sven A Miller; Steven Rogers; Jittasak Khowsathit; Lan Lan; Nan Bai; David K Johnson; Chunjing Liu; Liang Xu; Asokan Anbanandam; Jeffrey Aubé; Anuradha Roy; John Karanicolas
Journal:  J Med Chem       Date:  2015-07-10       Impact factor: 7.446

Review 3.  Compound activity prediction using models of binding pockets or ligand properties in 3D.

Authors:  Irina Kufareva; Yu-Chen Chen; Andrey V Ilatovskiy; Ruben Abagyan
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  Enrichment of chemical libraries docked to protein conformational ensembles and application to aldehyde dehydrogenase 2.

Authors:  Bo Wang; Cameron D Buchman; Liwei Li; Thomas D Hurley; Samy O Meroueh
Journal:  J Chem Inf Model       Date:  2014-06-30       Impact factor: 4.956

5.  Defining a new nomenclature for the structures of active and inactive kinases.

Authors:  Vivek Modi; Roland L Dunbrack
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

6.  Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.

Authors:  Sugandh Kumar; Bharati Singh; Pratima Kumari; Preethy V Kumar; Geetanjali Agnihotri; Shaheerah Khan; Tushar Kant Beuria; Gulam Hussain Syed; Anshuman Dixit
Journal:  Comput Struct Biotechnol J       Date:  2021-04-07       Impact factor: 7.271

7.  Identification and validation of novel PERK inhibitors.

Authors:  Qiantao Wang; Jihyun Park; Ashwini K Devkota; Eun Jeong Cho; Kevin N Dalby; Pengyu Ren
Journal:  J Chem Inf Model       Date:  2014-05-05       Impact factor: 4.956

8.  Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology.

Authors:  Zheng Zhao; Che Martin; Raymond Fan; Philip E Bourne; Lei Xie
Journal:  BMC Bioinformatics       Date:  2016-02-18       Impact factor: 3.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.